Sumatriptan - Nonresponders: A survey in 366 migraine patients

Headache

Volumn 36, Issue 8, 1996, Pages 471-475

  Visser, W H ^a   De Vriend, R H M ^a   Jaspers, N H W M ^a   Ferrari, Michel D ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

acute treatment of migraine; headache relief; migraine; sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ONSET AGE; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; BODY MASS INDEX; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; QUESTIONNAIRES; RISK FACTORS; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0029818044     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.1996.3608471.x     Document Type: Article

References (13)

1. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1994;47:622-651.
2. Ferrari MD, James MH, Bates D, et al. Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences. Cephalalgia. 1994;14:330-338.
3. Rapoport AM, Visser WH, Cutler NR, et al. Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan. Neurology. 1995;45:1505-1509.
4. Wilkinson M, Pfaffenrath V, Schoenen J, Diener H-C, Steiner TJ. Migraine and cluster headache - their management with sumatriptan: a critical review of the current clinical experience. Cephalalgia. 1995;15:337-357.
5. Visser WH, de Vriend RHM, Jaspers NHWM, Ferrari MD. Sumatriptan in clinical practice; a two year review of 453 migraine patients. Neurology. 1995. In press.
6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
7. Sheftell FD, Weeks RE, Rapoport AM, Siegel S, Baskin S, Arrowsmitlh F. Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center. Headache. 1994;34:67-72.
8. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
9. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology. 1994;44:1587-1592.
10. Ferrari MD, Saxena PR. 5-HT, receptors in migraine pathophysiology and treatment. Eur J Neurol. 1995;2:5-21.
11. Visser WH, Burggraaf J, Muller LM, et al. Pharmacokinetic differences between migraine patients with and without headache relief and between patients with and without headache recurrence after sumatriptan. Br J Clin Pharmacol. 1995;39:572P.
12. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci. 1993;14:129-133.
13. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nature Med. 1995;1:658-660.